Literature DB >> 7691811

Activation of the SH2-containing phosphotyrosine phosphatase SH-PTP2 by its binding site, phosphotyrosine 1009, on the human platelet-derived growth factor receptor.

R J Lechleider1, S Sugimoto, A M Bennett, A S Kashishian, J A Cooper, S E Shoelson, C T Walsh, B G Neel.   

Abstract

Much progress has been made in elucidating early events in signal transduction by growth factor receptors with intrinsic tyrosine kinase activity. Upon ligand addition, these receptors dimerize and activate, becoming phosphorylated at a number of tyrosyl residues. These phosphorylation sites serve as docking points for proteins containing src homology-2 (SH2) domains. However, little is known about how phosphotyrosine phosphatases (PTPs), participate in these events. Recently, we and others molecularly cloned a ubiquitously expressed SH2 domain-containing PTP, SH-PTP2 (Syp, PTP1D, PTP2C), and found that it interacts directly with several activated growth factor receptors via its SH2 domains. Using a peptide competition assay, we now demonstrate that the major binding site for SH-PTP2 on the platelet-derived growth factor receptor is phosphotyrosine 1009. Immunoprecipitation studies indicate that SH-PTP2 is the previously unidentified "64-kDa" protein known to bind at this site. Addition of a phosphotyrosyl peptide comprising the region around Tyr-1009 stimulates SH-PTP2 activity 5-10-fold, whereas other phosphotyrosyl peptides from the platelet-derived growth factor receptor have no stimulatory effect. Our data suggest that binding of SH-PTP2 to the activated receptor in vivo should result in stimulation of SH-PTP2 activity.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7691811

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  72 in total

1.  The tyrosine phosphatase SHP-2 is required for sustained activation of extracellular signal-regulated kinase and epithelial morphogenesis downstream from the met receptor tyrosine kinase.

Authors:  C R Maroun; M A Naujokas; M Holgado-Madruga; A J Wong; M Park
Journal:  Mol Cell Biol       Date:  2000-11       Impact factor: 4.272

2.  Gab1 mediates hepatocyte growth factor-stimulated mitogenicity and morphogenesis in multipotent myeloid cells.

Authors:  Angelina Felici; Alessio Giubellino; Donald P Bottaro
Journal:  J Cell Biochem       Date:  2010-10-01       Impact factor: 4.429

3.  Control of oligodendrocyte generation and proliferation by Shp2 protein tyrosine phosphatase.

Authors:  Ying Zhu; Jinsil Park; Xuemei Hu; Kang Zheng; Hong Li; Qilin Cao; Gen-Sheng Feng; Mengsheng Qiu
Journal:  Glia       Date:  2010-09       Impact factor: 7.452

4.  Kinase activation through dimerization by human SH2-B.

Authors:  Masahiro Nishi; Eric D Werner; Byung-Chul Oh; J Daniel Frantz; Sirano Dhe-Paganon; Lone Hansen; Jongsoon Lee; Steven E Shoelson
Journal:  Mol Cell Biol       Date:  2005-04       Impact factor: 4.272

5.  Structure-based kinetic models of modular signaling protein function: focus on Shp2.

Authors:  Dipak Barua; James R Faeder; Jason M Haugh
Journal:  Biophys J       Date:  2007-01-05       Impact factor: 4.033

6.  Conformational changes induced in the protein tyrosine kinase p72syk by tyrosine phosphorylation or by binding of phosphorylated immunoreceptor tyrosine-based activation motif peptides.

Authors:  T Kimura; H Sakamoto; E Appella; R P Siraganian
Journal:  Mol Cell Biol       Date:  1996-04       Impact factor: 4.272

Review 7.  Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway.

Authors:  P C Heinrich; I Behrmann; G Müller-Newen; F Schaper; L Graeve
Journal:  Biochem J       Date:  1998-09-01       Impact factor: 3.857

8.  Structural and mechanistic insights into LEOPARD syndrome-associated SHP2 mutations.

Authors:  Zhi-Hong Yu; Jie Xu; Chad D Walls; Lan Chen; Sheng Zhang; Ruoyu Zhang; Li Wu; Lina Wang; Sijiu Liu; Zhong-Yin Zhang
Journal:  J Biol Chem       Date:  2013-03-01       Impact factor: 5.157

9.  Prolactin enhances insulin-like growth factor I receptor phosphorylation by decreasing its association with the tyrosine phosphatase SHP-2 in MCF-7 breast cancer cells.

Authors:  Kristopher C Carver; Timothy M Piazza; Linda A Schuler
Journal:  J Biol Chem       Date:  2010-01-15       Impact factor: 5.157

10.  Low-dose dasatinib rescues cardiac function in Noonan syndrome.

Authors:  Jae-Sung Yi; Yan Huang; Andrea T Kwaczala; Ivana Y Kuo; Barbara E Ehrlich; Stuart G Campbell; Frank J Giordano; Anton M Bennett
Journal:  JCI Insight       Date:  2016-12-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.